Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma.

CD8+ NGS cell sorting flow cytometry immunohistochemistry indolent molecular fingerprinting multifocal primary cutaneous T-lymphoma

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
20 Feb 2023
Historique:
received: 09 01 2023
revised: 03 02 2023
accepted: 16 02 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 26 2 2023
Statut: epublish

Résumé

We report the case of a patient who was referred to our institution with a diagnosis of CD4+ small/medium-sized pleomorphic lymphoma. At the time, the patient showed a plethora of lesions mainly localizing to the legs; thus, we undertook studies to investigate the lineage and immunophenotype of the neoplastic clone. Immunohistochemistry (IHC) showed marked CD4 and CD8 positivity. Flow cytometry (FCM) showed two distinct T-cell populations, CD4+ and CD8+ (+/- PD1), with no CD4/CD8 co-expression and no loss of panT-cell markers in either T-cell subset. FCM, accompanied by cell-sorting (CS), permitted the physical separation of four populations, as follows: CD4+/PD1-, CD4+/PD1+, CD8+/PD1- and CD8+/PD1+. TCR gene rearrangement studies on each of the four populations (by next generation sequencing, NGS) showed that the neoplastic population was of T-cytotoxic cell lineage. IHC showed the CD8+ population to be TIA-1+, but perforin- and granzyme-negative. Moreover, histiocytic markers did not render the peculiar staining pattern, which is characteristic of acral CD8+ T-cell lymphoma (PCACD8). Compared to the entities described in the 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas, we found that the indolent lymphoma described herein differed from all of them. We submit that this case represents a hitherto-undescribed type of CTCL.

Identifiants

pubmed: 36831170
pii: biomedicines11020634
doi: 10.3390/biomedicines11020634
pmc: PMC9953132
pii:
doi:

Types de publication

Case Reports

Langues

eng

Références

Br J Dermatol. 2015 Jun;172(6):1573-1580
pubmed: 25524664
Hematol Oncol. 2021 Jun;39 Suppl 1:46-51
pubmed: 34105822
Clin Exp Dermatol. 2010 Dec;35(8):892-6
pubmed: 20456402
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
J Hematop. 2008 Sep;1(2):97-109
pubmed: 19669208
Nat Rev Cancer. 2020 Jun;20(6):323-342
pubmed: 32249838
Am J Clin Pathol. 2013 Apr;139(4):491-514
pubmed: 23525618
J Cutan Pathol. 2013 Feb;40(2):248-58
pubmed: 23189944
Blood. 2003 May 1;101(9):3407-12
pubmed: 12522013
Mod Pathol. 2008 Jun;21(6):708-15
pubmed: 18311111
Haematologica. 2022 Mar 01;107(3):702-714
pubmed: 33792220
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Am J Surg Pathol. 2004 Jun;28(6):719-35
pubmed: 15166664
J Cutan Pathol. 2010 Jan;37(1):81-4
pubmed: 19602068
Am J Surg Pathol. 2012 Jan;36(1):109-16
pubmed: 21989349
Am J Clin Pathol. 2011 Feb;135(2):278-90
pubmed: 21228369
J Cutan Pathol. 2010 Sep;37(9):977-81
pubmed: 19891656
Nat Commun. 2017 Nov 10;8(1):1404
pubmed: 29123081
Am J Surg Pathol. 2007 Dec;31(12):1887-92
pubmed: 18043044
Blood. 2008 Jan 15;111(2):838-45
pubmed: 17934071
Cancer. 2003 Feb 1;97(3):610-27
pubmed: 12548603
Am J Dermatopathol. 2014 May;36(5):402-8
pubmed: 24394306
Histopathology. 2015 Oct;67(4):425-41
pubmed: 24438036

Auteurs

Tina Petrogiannis-Haliotis (T)

Division of Pathology, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.
Division of Hematology, Department of Medicine, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.

Kevin Pehr (K)

Division of Dermatology, Department of Medicine, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.

David Roberge (D)

Département de Radiologie, Radio-Oncologie et Médicine Nucléaire, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC H2W 1T8, Canada.

Ryan N Rys (RN)

Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.

Yury Monczak (Y)

Division of Pathology, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.
Division of Hematology, Department of Medicine, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.

Gizelle Popradi (G)

Division of Hematology, Department of Medicine, Royal Victoria Hospital, McGill University, Montréal, QC H4A 3J1, Canada.

Lissa Ajjamada (L)

Division of Hematology, Department of Medicine, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.

Naciba Benlimame (N)

Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.

Christiane Querfeld (C)

Division of Dermatology, City of Hope, Duarte, CA 91010, USA.

Nathalie Johnson (N)

Division of Hematology, Department of Medicine, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.
Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.

Hans Knecht (H)

Division of Hematology, Department of Medicine, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.

Classifications MeSH